Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis. METHODS MESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18-50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2-15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2·5-6·5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit. FINDINGS From July 16, 2012, until July 31, 2019, 144 patients were randomly assigned to first receive early intravenous infusion of autologous bone marrow-derived MSCs (n=69) or placebo (n=75). MSC treatment did not meet the primary endpoint of efficacy on the total number of GELs accumulated from baseline to week 24 (rate ratio [RR] 0·94, 95% CI 0·58-1·50; p=0·78). 213 adverse events were recorded, similarly distributed between groups (93 cases recorded in 35 [51%] of 69 patients treated first with MSCs vs 120 cases in 42 [56%] of 75 patients infused first with placebo). The most frequent adverse events reported were infection and infestations, with a total of 54 (25%) of 213 adverse events (18 [19%] of 93 in the early-MSC group and 36 [30%] of 120 in the delayed-MSC group). Nine serious adverse events were reported in seven patients treated with placebo versus none in the MSC group. All serious adverse events were considered to be unrelated to the treatment infusion. No deaths were reported during the study. INTERPRETATION Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on GELs, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24. Thus, this study does not support the use of bone marrow-derived MSCs to treat active multiple sclerosis. Further studies should address the effect of MSCs on parameters related to tissue repair. FUNDING Fondazione Italiana Sclerosi Multipla (FISM), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the Multiple Sclerosis International Federation (MSIF) for centralised activities. Individual trials participating in the MESEMS network are funded by the following agencies: FISM and Compagnia di San Paolo (Italy); The Danish Multiple Sclerosis Society, The Toyota Foundation, and Danish Blood Donors' Research Foundation (Denmark); the Spanish Health Research Institute Carlos 3 and the Andalusian Public Foundation Progreso y Salud (Spain); the Royan Institute for Stem Cell Biology and Technology (Iran); the Spinal Cord Injury and Tissue Regeneration Centre Salzburg, Paracelsus Medical University, and Salzburg (Austria); the Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon (France); the UK Multiple Sclerosis Society and the UK Stem Cell Foundation (UK); and the Multiple Sclerosis Society of Canada and The Multiple Sclerosis Scientific Research Foundation and Research Manitoba (Canada).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationLee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
Are animal models predictive for humans?
Shanks, N., Greek, R., & Greek, J. (2009) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-4-2 · Cited by 677
Bai, L., Lennon, D. P., Caplan, A. I., DeChant, A., Hecker, J., Kranso, J., Zaremba, A., & Miller, R. H. (2012) · Nature Neuroscience · doi:10.1038/nn.3109 · Cited by 421
Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo
Lanza, C., Morando, S., Voci, A., Canesi, L., Principato, M. C., Serpero, L. D., Mancardi, G., Uccelli, A., & Vergani, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06268.x · Cited by 175
Self-citation
Cited by
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Scalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Metadata
- Authors
- Uccelli, A., Laroni, A., Ali, R., Battaglia, M. A., Blinkenberg, M., Brundin, L., Clanet, M., Fernandez, O., Marriott, J., Muraro, P., Nabavi, S. M., Oliveri, R. S., Radue, E., Ramo Tello, C., Schiavetti, I., Sellner, J., Sorensen, P. S., Sormani, M. P., Wuerfel, J. T., Freedman, M. S., Aghdami, N., Agüera-Morales, E., Ali, R., Allan, D., Arab, L., Battaglia, M., Berry, I., Blinkenberg, M., Bonetti, B., Brundin, L., Capelli, C., Castellan, L., Cellerino, M., Cencioni, M. T., Clanet, M., Comi, G., Courtman, D., Dazzi, F., Fischer-Nielsen, A., Fernandez, O., Fernandez, V., Freedman, M. S., Furlan, R., Gimona, M., Gualandi, F., Guan, Q., Iacobaeus, E., Inglese, M., Introna, M., Izquierdo, G., Karimi, S., Laroni, A., Le Blanc, K., Loaiza, S., Mallik, S., Marley, S., Marrie, R. A., Marriot, J., Martino, G., Nabavi, S. M., Miller, D., Muraro, P. A., Nicholas, R., Oliveri, R. S., Orengo, G., Palanicawande, R., Pardini, M., Radue, E. W., Ramo Tello, C., Rush, C., Schiavetti, I., Sellner, J., Sensebe, L., Soelberg Sorensen, P., Sormani, M. P., Strunk, D., Szwajcer, D., Thalamas, C., Uccelli, A., & Wuerfel, J. T.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 20
- Issue
- 11
- Pages
- 917-929
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3206255287
- Cited by
- 110
- References
- 7
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. https://app.cochat.ai/papers/10.1016/s1474-4422(21)00301-x
- The paper
- Uccelli, A., Laroni, A., Ali, R., Battaglia, M. A., Blinkenberg, M., Brundin, L., Clanet, M., Fernandez, O., Marriott, J., Muraro, P., Nabavi, S. M., Oliveri, R. S., Radue, E., Ramo Tello, C., Schiavetti, I., Sellner, J., Sorensen, P. S., Sormani, M. P., Wuerfel, J. T., . . . Wuerfel, J. T. (2021). Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(21)00301-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.